"Share the Freedom" detail aid includes unsupported comparative clinical superiority claims for fexofenadine versus Schering-Plough's Claritin (loratadine), FDA says in April 8 notice of violation letter to Hoechst Marion Roussel. The detail aid used pharmacodynamic wheal and flare data to suggest that "Allegra produced significantly greater suppression of wheal areas than loratadine." FDA also cited a Pfizer Zyrtec brochure in a March 4 letter for comparisons between Zyrtec, Claritin, HMR's Seldane and Janssen's Hismanal based on the wheal/flare suppression test
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth